Salix Pharmaceuticals Receives Average Rating of “Buy” from Brokerages (NASDAQ:SLXP)
Salix Pharmaceuticals (NASDAQ:SLXP) has received a consensus rating of “Buy” from the twenty brokerages that are currently covering the company, AR Network reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $136.98.
Shares of Salix Pharmaceuticals (NASDAQ:SLXP) opened at 158.30 on Monday. Salix Pharmaceuticals has a 52 week low of $64.93 and a 52 week high of $162.38. The stock’s 50-day moving average is $135.7 and its 200-day moving average is $115.9. The company has a market cap of $10.082 billion and a price-to-earnings ratio of 174.06.
Salix Pharmaceuticals (NASDAQ:SLXP) last announced its earnings results on Thursday, August 7th. The company reported $1.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.69 by $0.10. The company had revenue of $382.00 million for the quarter, compared to the consensus estimate of $397.06 million. During the same quarter in the previous year, the company posted $0.87 earnings per share. The company’s revenue for the quarter was up 62.3% on a year-over-year basis. On average, analysts predict that Salix Pharmaceuticals will post $6.17 earnings per share for the current fiscal year.
SLXP has been the subject of a number of recent research reports. Analysts at JMP Securities reiterated a “market outperform” rating on shares of Salix Pharmaceuticals in a research note on Wednesday. They now have a $190.00 price target on the stock, up previously from $173.00. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Salix Pharmaceuticals in a research note on Wednesday, August 13th. They now have a $153.00 price target on the stock. Finally, analysts at Jefferies Group downgraded shares of Salix Pharmaceuticals to a “neutral” rating in a research note on Friday, August 8th.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.